CompletedPhase 2NCT00844298
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Asan Medical Center
- Principal Investigator
- Kyoo H. Lee, MDAsan Medical Center
- Intervention
- Nilotinib+mVPD(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2009 – 2014
Study locations (16)
- Daegu Fatima Hospital, Daegu, South Korea
- Kyungpook National University Hospital, Daegu, South Korea
- Yeungnam University Medical Center, Daegu, South Korea
- Daegu Catholic University Hospital, Daegu, South Korea
- National Cancer Center - Korea, Goyang, South Korea
- Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
- Gyeongsang National University Hospital, Jinju, South Korea
- Pusan National University Hospital, Pusan, South Korea
- Inje University Seoul Paik Hospital, Seoul, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Kyung Hee University Hospital, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- Asan Medical Center - University of Ulsan College of Medicine, Seoul, South Korea
- Konkuk University Medical Center, Seoul, South Korea
- Ajou University Hospital, Suwon, South Korea
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00844298 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →